Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Atea Pharmaceuticals Inc

Healthcare US AVIR

4.39USD
0.03(0.69%)

Last update at 2026-06-22T20:00:00Z

Day Range

4.324.48
LowHigh

52 Week Range

2.466.45
LowHigh

Fundamentals

  • Previous Close 4.36
  • Market Cap454.93M
  • Volume354923
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-178.98099M
  • Revenue TTM192.18M
  • Revenue Per Share TTM2.31
  • Gross Profit TTM -146.53400M
  • Diluted EPS TTM-1.94

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -164.51100M -167.46000M -134.93800M -119.49900M 138.59M
Minority interest - - - - -
Net income -158.34900M -168.38500M -135.95600M -115.90900M 121.19M
Selling general administrative 32.86M 48.85M 49.92M 48.71M 45.78M
Selling and marketing expenses - - 49.45M - -
Gross profit -0.41600M -83.36700M -70.09000M - 351.37M
Reconciled depreciation 0.42M 0.42M 0.42M 0.26M 0.03M
Ebit -181.30300M -132.21600M -120.00900M -130.91000M 138.35M
Ebitda -180.88700M -131.80000M -119.59300M -130.65000M 138.38M
Depreciation and amortization 0.42M 0.42M 0.42M 0.26M 0.03M
Non operating income net other - - - - 0.21M
Operating income -180.88700M -192.95000M -164.16200M -130.65000M 138.38M
Other operating expenses 180.89M 192.95M 164.16M 130.65M 212.99M
Interest expense - - - 11.15M 0.24M
Tax provision -6.16200M 0.93M 1.02M -3.59000M 17.40M
Interest income 16.38M 25.49M 29.22M 11.15M 0.21M
Net interest income 16.38M 25.49M 29.22M 11.15M 0.21M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -6.16200M 0.93M 1.02M -3.59000M 17.40M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 351.37M
Total operating expenses 180.89M 109.58M 94.07M 130.65M 212.99M
Cost of revenue 0.42M 83.37M 70.09M - -
Total other income expense net 16.38M 25.49M 29.22M 11.15M 0.21M
Discontinued operations - - - - -
Net income from continuing ops -158.34900M -168.38500M -135.95600M -115.90900M 121.19M
Net income applicable to common shares - - - -115.90900M 121.19M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 315.22M 464.67M 594.97M 666.71M 772.89M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 9.16M 7.63M 12.35M 14.21M 8.03M
Total liab 39.78M 25.80M 39.78M 26.14M 62.81M
Total stockholder equity 275.43M 438.87M 555.19M 640.57M 710.08M
Deferred long term liab - - - - -
Other current liab 26.00M 13.35M 27.36M 15.21M 52.35M
Common stock 0.08M 0.08M 0.08M 0.08M 0.08M
Capital stock 0.08M 0.08M 0.08M 0.08M 0.08M
Retained earnings -522.56900M -364.22000M -195.83500M -59.87900M 56.03M
Other liab - - - 5.25M 5.93M
Good will - - - - -
Other assets - - 0.00000M 1.69M 0.47M
Cash 95.71M 64.70M 143.82M 646.71M 764.38M
Cash and equivalents - - - - -
Total current liabilities 39.78M 18.60M 32.38M 18.48M 56.88M
Current deferred revenue - - -0.00000M - -
Net debt -94.87000M -63.05400M -141.42100M -643.58500M -764.37500M
Short term debt 0.84M 0.80M 0.76M 0.72M -
Short long term debt - - - - -
Short long term debt total 0.84M 1.64M 2.40M 3.12M -
Other stockholder equity 797.75M 802.77M 750.74M 701.05M 653.96M
Property plant equipment - - - 4.09M 0.02M
Total current assets 310.99M 462.36M 590.46M 660.92M 772.40M
Long term investments - - - - -
Net tangible assets - - - 640.57M 710.08M
Short term investments 206.12M 390.02M 434.28M 458.25M -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 12.95M 4.46M 4.25M 2.55M 4.53M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.17M 0.23M 0.21M -0.68400M -
Additional paid in capital - - - - -
Common stock total equity - - - - 0.08M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - 56.03M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.14M 0.20M 1.40M 1.69M 0.47M
Deferred long term asset charges - - - - -
Non current assets total 4.23M 2.31M 4.51M 5.79M 0.49M
Capital lease obligations 0.84M 1.64M 2.40M 3.12M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 188.79M 56.10M 40.30M -455.41000M -0.00400M
Change to liabilities - - - -1.98300M -291.07800M
Total cashflows from investing activities 188.79M 56.10M 40.30M -455.41000M -0.00400M
Net borrowings - - - - -
Total cash from financing activities -25.74500M 0.27M 0.26M 0.37M 1.47M
Change to operating activities - - - -44.60300M 43.23M
Net income -158.34900M -168.38500M -135.95600M -115.90900M 121.19M
Change in cash 31.02M -79.12700M -44.83500M -576.02200M -85.54400M
Begin period cash flow 64.70M 143.82M 188.66M 764.68M 850.22M
End period cash flow 95.71M 64.70M 143.82M 188.66M 764.68M
Total cash from operating activities -132.03100M -135.49900M -85.39500M -120.98200M -87.00500M
Issuance of capital stock 0.06M 0.00000M - 0.23M 1.47M
Depreciation 0.42M 0.42M 0.42M 0.26M 0.03M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock -25.51900M 0.00000M - - 1.47M
Other cashflows from financing activities -0.48500M 0.27M 0.26M 0.14M -0.00400M
Change to netincome - - - 41.25M 39.62M
Capital expenditures 0.00000M 0.00000M 0.00000M 1.94M 0.00400M
Change receivables - - - - -
Cash flows other operating - - - - -302.01100M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -85.54400M
Change in working capital 16.48M -7.47600M 16.16M -46.58600M -247.84500M
Stock based compensation 20.72M 51.77M 49.43M 46.72M 39.62M
Other non cash items -4.94400M -11.82100M 33.11M -5.46500M -415.68300M
Free cash flow -132.03100M -135.49900M -85.39500M -122.92500M -87.00900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVIR
Atea Pharmaceuticals Inc		 0.03 0.69% 4.39 - - 1.55 1.66 58.97 -260.4742
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Atea Pharmaceuticals Inc

225 Franklin Street, Boston, MA, United States, 02110

Key Executives

Name Title Year Born
Dr. Jean-Pierre Sommadossi Ph.D. Founder, Chairman, CEO & Pres 1956
Ms. Andrea J. Corcoran J.D. CFO, Exec. VP of Legal & Sec. 1962
Mr. John F. Vavricka Chief Commercial Officer 1964
Dr. Janet M. J. Hammond M.D., Ph.D. Chief Devel. Officer 1960
Dr. Maria Arantxa Horga M.D. Chief Medical Officer 1968
Mr. Wayne Foster CPA, CPA Exec. VP of Fin. & Chief Accounting Officer 1969
Ms. Jonae R. Barnes Sr. VP of Investor Relations & Corp. Communications NA
Mr. Ariyapadi N. Krishnaraj VP of Marketing NA
Mr. Adel Moussa Ph.D. Exec. VP of Chemistry NA
Mr. Xiao-Jian Zhou Ph.D. Exec. VP of Early Stage Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.